Allergy Therapeutics plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AGYTF research report →
Companywww.allergytherapeutics.com
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut.
- CEO
- Manuel Llobet
- IPO
- 2010
- Employees
- 612
- HQ
- Worthing, GB
Price Chart
Valuation
- Market Cap
- $554.62M
- P/E
- -10.33
- P/S
- 8.52
- P/B
- 119.03
- EV/EBITDA
- -15.42
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 41.17%
- Op Margin
- -60.23%
- Net Margin
- -85.46%
- ROE
- 409.00%
- ROIC
- -84.29%
Growth & Income
- Revenue
- $75.56M · 36.89%
- Net Income
- $-55,093,209 · -36.99%
- EPS
- $-0.01 · 21.50%
- Op Income
- $-28,162,000
- FCF YoY
- -23.54%
Performance & Tape
- 52W High
- $0.11
- 52W Low
- $0.09
- 50D MA
- $0.11
- 200D MA
- $0.10
- Beta
- 0.89
- Avg Volume
- 8
Get TickerSpark's AI analysis on AGYTF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our AGYTF Coverage
We haven't published any research on AGYTF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AGYTF Report →